HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (NASDAQ:ARDM) (the “Company”) today announced the upcoming presentation of research at the European Respiratory Society (ERS) 2017 Annual Congress, the world’s largest meeting of respiratory professionals, taking place in Milan, Italy from September 9-13.
Data to be shared include two late-breaking oral presentations, titled:
• “Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis patients is independent of Pseudomonas aeruginosa susceptibility at baseline” (Sunday, 10 September at 10:45 am CEST)
• “The prevalence and burden of Pseudomonas aeruginosa among bronchiectasis patients in Europe – data from the FRIENDS cohort” (Monday, 11 September at 10:45 am CEST)
The first study will be presented by Aradigm. Aradigm is developing Linhaliq™ (ARD-3150), an investigational inhaled ciprofloxacin product candidate. The second study to be presented by Dr. James Chalmers evaluated the rate of chronic infection with P. aeruginosa among bronchiectasis patients in Europe, as well as burden of disease, mortality and overall quality of life.
“Resistance to antibiotics in patients with chronic infections is a major therapeutic challenge. Based on our Phase 3 clinical trials in non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aeruginosa, the high persistent ciprofloxacin concentrations resulting from once daily inhaled doses of Linhaliq appear to overcome this problem, as seen by a reduction of infectious pulmonary exacerbations across patients with resistant and non-resistant P. aeruginosa isolates,” said Dr. Juergen Froehlich, Chief Medical Officer, Aradigm Corporation.
About Non-Cystic Fibrosis Bronchiectasis
Non-cystic fibrosis bronchiectasis (NCFBE) is a severe, chronic and rare disease characterized by abnormal dilatation of the bronchi and bronchioles, frequently associated with chronic lung infections. It is often a consequence of a vicious cycle of inflammation, recurrent lung infections, and bronchial wall damage. NCFBE represents an unmet medical need with high morbidity and mortality that affects more than 150,000 people in the U.S. and over 200,000 people in Europe. There is currently no drug approved for the treatment of this condition. NCFBE patients who have chronic infections with P. aeruginosa have a 6.5-fold increase in hospitalization, three times higher mortality, and a worse quality of life compared with those without P. aeruginosa infections.
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm has completed two Phase 3 clinical trials with Linhaliq (ARD-3150), an investigational proprietary formulation of ciprofloxacin for inhalation, for the treatment of NCFBE and submitted a New Drug Application to the FDA for this indication. Aradigm's inhaled ciprofloxacin formulations, including Linhaliq, are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
More information about Aradigm can be found at www.aradigm.com.
Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation. Linhaliq is a registered trademark of Grifols, S.A.